The antihyperlipidemic effects of fullerenol nanoparticles via adjusting the gut microbiota in vivo.

ABSTRACT:

Background

Nanoparticles (NPs) administered orally will meet the gut microbiota, but their impacts on microbiota homeostasis and the consequent physiological relevance remain largely unknown. Here, we describe the modulatory effects and the consequent pharmacological outputs of two orally administered fullerenols NPs (Fol1 C₆₀(OH)₇(O)₈ and Fol113 C₆₀(OH)₁₁(O)₆) on gut microbiota.

Results

Administration of Fol1 and Fol113 NPs for 4 weeks largely shifted the overall structure of gut microbiota in mice. The bacteria belonging to putative short-chain fatty acids (SCFAs)-producing genera were markedly increased by both NPs, especially Fol1. Dynamic analysis showed that major SCFAs-producers and key butyrate-produci

SUBMITTER: Li J 

PROVIDER: S-EPMC5773151 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature